Revvity Launches Cloud-Native Platform to Accelerate Molecular Cloning

Revvity, Inc. has introduced Signals BioDesign, a high-throughput cloud-native platform designed to streamline R&D workflows for pharmaceutical and biotech companies. The platform allows researchers to design up to 1,000 molecular constructs while supporting various cloning methodologies and providing AI-ready data infrastructure for future machine learning applications. By integrating with the Signals One ecosystem, the tool ensures centralized data management and enhances collaboration across research teams. In conjunction with this launch, analysts have recently adjusted price targets for Revvity's stock, reflecting optimism toward the company's digital transformation. This strategic expansion of the life sciences portfolio aims to prepare research workflows for advanced AI integration. The innovation underscores Revvity's commitment to improving operational efficiency and increasing its market share in the lab software sector.